Just to show how little it knows. It goes on to write MSO investors are far better off. By what metrics does it use? Does it wait for fomo pumps that temporarily net Curaleaf one percent of Volume Tilray and Canadian Lps receive and then claim Candian LP's ride MSO coat tails? It made this claim. It also made the claim being on the Nasdaq wasn't an advantage to MSO and we were forced to link a post article of Borris Jordan releasing a statement that he hopes Curaleaf can find a path to uplist to the tsx in order to attract at least some institutional investment and more liquid volume. It doesn't understand Curaleaf is sitting on a mountain of goodwill and riding high on some possible but unlikely regulatory news that would take years to work out the framework. Even after it's fomo pump with little volume if you bought Curaleaf a year ago and Tilray a year ago you would be down 16 percent with Curaleaf and 2.5 percent with Tilray. So anything kelller claims depends on the point of view it chooses. I try to help it understand the workings of the market